Replies to post #476009 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Anybody else think the early vanguard group is the one that primarily makes up the 24 unidentified mgmt in the noncrossover group?

100% I agree. I think patients and doctors didn’t know enough about DCVax effectiveness particularly at crossover back in the early days of the trial so they moved on to other trials, and there were a few back then, or simply died early.

[Doc logic]

flipper44,

One other piece of this puzzle maybe unrelated but not sure,
is the experience RKmatters reported with her nephew about not PFS eventing until too late to cross over. He was younger, probably proneural, IDH status unknown to us and late to PFS event. How many like him help explain the drop off in survival after 36 months? Best wishes.

[skitahoe]

Flipper,

I know people are reticent to discuss deaths, or events as the FDA chooses to call them, but this is a very deadly cancer. I believe that most who failed to cross over had either passed on, or been too sick to take the treatment, by the time the treatment was properly offered to them. It's not about not choosing to take it, it's about life ending events occurring before such an option was available.

Perhaps in the Journal they'll go into depth on the patients who didn't cross over, then we'll know. I frankly don't believe that any entering the trial had forms of brain cancers that weren't deadly to well over 90% of them, not crossing over is very probably because you couldn't, not because you didn't choose to.

Gary

[GermanCol]

Anybody else think the early vanguard group is the one that primarily makes up the 24 unidentified mgmt in the noncrossover group?

Me, I think that is the case. From JTM article:

The MGMT gene promoter was methylated in 39.6% of patients (n=131) and unmethylated in 48.9% (n=162), with information not available for 11.5% (n=38; the missing data relates to the early patients enrolled a decade ago)

I also want to clarify that I don´t know if the 35 non crossover patients as a whole did well or better than the other patients. What I have been saying is that from my calculations I conclude that there is a higher percentage of MGMT Methylated and IDH-1 mutated in that group. And these patients are expected to do better, so in case the whole group of 35 did better than the others, there is no reason to worry about.

I agree that in this group there should have been also progressors that didn't make it to crossover and didn't do well. Also I think in this group there are patients that opted for other treatments after progressing and probably weren't followed anymore.